JP2018532736A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532736A5
JP2018532736A5 JP2018519039A JP2018519039A JP2018532736A5 JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5 JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5
Authority
JP
Japan
Prior art keywords
neoepitope
matched
hla
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018519039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056692 external-priority patent/WO2017066357A1/en
Publication of JP2018532736A publication Critical patent/JP2018532736A/ja
Publication of JP2018532736A5 publication Critical patent/JP2018532736A5/ja
Pending legal-status Critical Current

Links

JP2018519039A 2015-10-12 2016-10-12 チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法 Pending JP2018532736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240494P 2015-10-12 2015-10-12
US62/240,494 2015-10-12
PCT/US2016/056692 WO2017066357A1 (en) 2015-10-12 2016-10-12 Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2018532736A JP2018532736A (ja) 2018-11-08
JP2018532736A5 true JP2018532736A5 (https=) 2019-01-17

Family

ID=57882841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519039A Pending JP2018532736A (ja) 2015-10-12 2016-10-12 チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法

Country Status (10)

Country Link
US (2) US11626187B2 (https=)
EP (1) EP3362930A4 (https=)
JP (1) JP2018532736A (https=)
KR (1) KR20180087244A (https=)
CN (1) CN108701173A (https=)
AU (1) AU2016339035A1 (https=)
CA (1) CA3003251A1 (https=)
HK (1) HK1258091A1 (https=)
IL (1) IL258679A (https=)
WO (1) WO2017066357A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA3003251A1 (en) 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
WO2017139694A1 (en) 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
EP3500966B1 (en) 2016-08-25 2021-04-21 Nantomics, LLC Immunotherapy markers and uses therefor
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
WO2018237088A1 (en) * 2017-06-20 2018-12-27 Bio-Rad Laboratories, Inc. DIGITAL AMPLIFICATION ASSAYS FOR GENETIC INSTABILITY
US11918634B2 (en) * 2017-08-10 2024-03-05 Good T Cells, Inc. Method for activating T cells for cancer treatment
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
WO2019133391A1 (en) * 2017-12-20 2019-07-04 Nantomics, Llc Using cfrna for diagnosing minimal residual disease
WO2019206725A1 (en) * 2018-04-25 2019-10-31 Koninklijke Philips N.V. Tumor functional mutation and epitope loads as improved predictive biomarkers for immunotherapy response
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
WO2020041561A1 (en) * 2018-08-23 2020-02-27 Nantcell, Inc. Assessing microsatellite instability by liquid biopsy
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
WO2020091944A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Genomic and immune infiltration differences between msi and mss gi tumors
CN110556164B (zh) * 2019-09-09 2023-02-07 深圳裕策生物科技有限公司 用于目标区域捕获测序检测msi的方法、装置和存储介质
CN110910957B (zh) * 2019-12-31 2023-06-27 求臻医学科技(浙江)有限公司 一种基于单肿瘤样本高通量测序微卫星不稳定性探测位点筛选方法
CN111785324B (zh) * 2020-07-02 2021-02-02 深圳市海普洛斯生物科技有限公司 一种微卫星不稳定分析方法及装置
CN112183557A (zh) * 2020-09-29 2021-01-05 山西医科大学 基于胃癌组织病理图像纹理特征的msi预测模型构建方法
CN114974420A (zh) * 2021-10-29 2022-08-30 无锡臻和生物科技有限公司 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207459A1 (en) 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
DK1601450T3 (da) 2003-03-10 2013-09-08 Expression Pathology Inc Flydende vævspræparat ud fra histopatologisk bearbejdede biologiske prøver, væv og celler
CA2535976A1 (en) 2003-08-20 2005-03-03 Cleveland Clinic Foundation A novel gene and protein associated with angiogenesis and endothelial apoptosis
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
US7811993B2 (en) 2005-06-29 2010-10-12 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
KR102042253B1 (ko) 2010-05-25 2019-11-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Bambam:고처리율 서열분석 데이터의 병렬 비교 분석
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
AU2014337063A1 (en) 2013-10-18 2016-05-19 Adaptive Biotechnologies Corp. Predicting patient responsiveness to immune checkpoint inhibitors
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3090066A4 (en) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
AU2016311444B2 (en) 2015-08-25 2019-02-07 Nantomics, Llc Systems and methods for high-accuracy variant calling
CA3003251A1 (en) 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors

Similar Documents

Publication Publication Date Title
JP2018532736A5 (https=)
JP7851982B2 (ja) 癌のための個別化ワクチン
Stange et al. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15. 5 gain
Bolton et al. Noncoding RNAs in prostate cancer: the long and the short of it
TWI642786B (zh) 與癌症有關之基因或分子變異之檢測
US20230335219A1 (en) Methods and systems for detecting insertions and deletions
JP2018510657A5 (https=)
Espinosa‐Parrilla et al. Genetic association of gastric cancer with miRNA clusters including the cancer‐related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC‐EURGAST study
JP2019512014A (ja) がん診断法および治療法におけるpiRNAを使用する組成物および方法
CN107075730A (zh) 循环核酸的鉴定及用途
Plieskatt et al. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma
JP2019517781A5 (https=)
JP2018532736A (ja) チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法
Guo et al. Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma
Murphy et al. Length variations within the Merle retrotransposon of canine PMEL: correlating genotype with phenotype
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
Omrane et al. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer
JP2012531210A5 (https=)
JP2024528489A5 (https=)
Wang et al. Identification of two disease-causing genes TJP2 and GJB2 in a Chinese family with unconditional autosomal dominant nonsyndromic hereditary hearing impairment
JP2024512372A (ja) オフターゲットポリヌクレオチド配列決定データに基づく腫瘍の存在の検出
KR102238912B1 (ko) Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
Sakthianandeswaren et al. Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing
CN110462063A (zh) 一种基于测序数据的变异检测方法、装置和存储介质
DE112005001317A5 (de) Polymorphismen im NOD2/Card15 Gen